Yuan Gui
Nanjing Medical University
23 Papers
23 Citations
Yuan Gui is an academic researcher from Nanjing Medical University. The author has contributed to research in topics: Medicine & Kidney. The author has an hindex of 9, co-authored 18 publications. Previous affiliations of Yuan Gui include University of Connecticut Health Center & Roy J. and Lucille A. Carver College of Medicine.
Chat about Author
Papers
Wnt/ β -Catenin-Promoted Macrophage Alternative Activation Contributes to Kidney Fibrosis.
Ye Feng,Jiafa Ren,Yuan Gui,Wei Wei,Bingyan Shu,Qingmiao Lu,Xian Xue,Xiaoli Sun,Weichun He,Junwei Yang,Chunsun Dai +10 more
TL;DR: It is shown that activation of Wnt/β-catenin signaling promotes kidney fibrosis by stimulating macrophage M2 polarization and preventing IL-4- or TGFβ1-induced Macrophage alternative (M2) polarization processes.
219
Metformin Protects Against Cisplatin-Induced Tubular Cell Apoptosis and Acute Kidney Injury via AMPKα-regulated Autophagy Induction
Jianzhong Li,Yuan Gui,Jiafa Ren,Xin Liu,Ye Feng,Zhifeng Zeng,Weichun He,Junwei Yang,Chunsun Dai +8 more
TL;DR: It is demonstrated that metformin may protect against cisplatin-induced tubular cell apoptosis and AKI through stimulating AMPKα activation and autophagy induction in the tubular cells.
Blockade of CD38 diminishes lipopolysaccharide-induced macrophage classical activation and acute kidney injury involving NF-κB signaling suppression.
Bingyan Shu,Ye Feng,Yuan Gui,Qingmiao Lu,Wei Wei,Xian Xue,Xiaoli Sun,Weichun He,Junwei Yang,Chunsun Dai +9 more
TL;DR: It is reported that in cultured macrophages, Lipopolysaccharide (LPS) could upregulate CD38 expression in time and dose dependent manner and CD38 mediates LPS-induced macrophage activation and AKI, which may be treated as a therapeutic target for sepsis-induced AKI in patients.
77
Yap/Taz mediates mTORC2-stimulated fibroblast activation and kidney fibrosis
TL;DR: Targeting mTORC2 retards fibroblast activation and kidney fibrosis through suppressing Yap/Taz activation in mice is uncovered.
56
Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis.
Ning Li,Dan Lv,Xiangjun Zhu,Ping Wei,Yuan Gui,Shijia Liu,Enchao Zhou,Min Zheng,Dong Zhou,Lu Zhang +9 more
TL;DR: In this article, the authors systematically searched the Embase, PubMed, Web of Science, and Cochrane library databases from inception to April 15, 2021 to identify eligible trials and found that SGLT2 inhibitors significantly reduced the risk of the primary outcome in CKD patients.
42